TriCaprin Benefits:
What the Research Says About C10 Triglycerides

1. What Is TriCaprin?

Tricaprin is a fat molecule. Its scientific name is glyceryl tricaprate. It is made of three capric acid chains attached to a glycerol backbone. Capric acid is also known as C10 because it has 10 carbon atoms in its chain.

Fats come in different sizes. Short-chain fats have fewer than 6 carbons. Long-chain fats — like those in olive oil or butter — have 12 or more. Capric acid sits in the middle. This is why it belongs to a group called medium-chain triglycerides, or MCTs.

Tricaprin is found naturally in small amounts in goat's milk, coconut oil, and palm kernel oil. It can also be made in a laboratory from capric acid and glycerol.

What makes tricaprin special is not just where it comes from — it is how the body processes it. Unlike long-chain fats, tricaprin does not follow the usual route through the lymphatic system. Instead, it goes directly to the liver through the blood. This shortcut has a big effect on how the body uses it as fuel.

2. How TriCaprin Works in Metabolism

When you eat most fats, your digestive system packages them into particles called chylomicrons. These travel through the lymphatic system before entering the bloodstream. This is a slow, multi-step process.

Tricaprin skips this entirely. Because C10 is a medium-chain fat, it is absorbed directly into the portal vein — the blood vessel that goes straight to the liver. The liver then processes it quickly.

In the liver, C10 can be converted into ketone bodies. Ketones are a type of fuel that the brain, muscles, and other organs can use for energy. This is different from sugar (glucose), which is the body's usual fuel. When the body uses ketones alongside glucose, it creates a mixed energy system that some researchers believe may be more efficient in certain situations.

C10 also appears to interact with a protein called PPARγ (say: "pee-par gamma"). PPARγ is a master switch inside cells that controls how fats are metabolized and how mitochondria are maintained. Mitochondria are the tiny parts of cells that make energy. Research published in the Journal of Neurochemistry in 2014 showed that C10 — specifically, not C8 — activates PPARγ and increases the activity of energy-making machinery inside mitochondria. Deep Dive: C10 vs. C8

3. Potential Metabolic Benefits

Researchers have explored several possible metabolic effects of tricaprin and C10. It is important to say that much of this research is still early-stage. Some studies were done in animals or in cell labs — not in large groups of people. But the findings point to interesting directions worth understanding.

One key difference from other saturated fats: C10 does not seem to raise "bad" LDL cholesterol. Long-chain saturated fats — like palmitic acid found in red meat — are well-documented to raise LDL. C10 takes a different metabolic path and does not go through the same steps that raise LDL levels.

This distinction matters because it means tricaprin behaves differently than what most people think of when they hear "saturated fat." The body treats different fat chain lengths very differently.

4. TriCaprin and GLP-1 Signaling

GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases after you eat. GLP-1 helps control blood sugar, slows digestion, and sends fullness signals to the brain. It has become famous because GLP-1 receptor agonist drugs — like semaglutide (Ozempic, Wegovy) — are built to mimic or boost this hormone.

Interestingly, research suggests that C10 may naturally stimulate GLP-1 release. When C10 reaches the gut, it appears to trigger the release of both GLP-1 and another hormone called GIP. Together, these hormones help manage blood sugar and appetite.

C10 has also been shown to raise levels of a molecule called acyl-ghrelin. This is the active form of ghrelin — the hormone often called the "hunger hormone." But acyl-ghrelin does something else too: it stimulates the release of growth hormone (GH). Growth hormone is important for muscle building, fat metabolism, and recovery.

As we age, growth hormone levels naturally fall. The idea that a dietary fat could partially stimulate this hormonal pathway is one reason researchers find C10 interesting — especially for older adults whose anabolic (muscle-building) hormones are already declining.

5. TriCaprin and Muscle Metabolism

One of the most studied areas of C10 research is its effect on muscle tissue — particularly in older adults. Muscle loss with aging is called sarcopenia. It is extremely common. After age 60, people can lose 2–3% of their muscle strength every year if they do not take steps to preserve it.

A research team at Showa Women's University in Tokyo ran three clinical trials between 2016 and 2023. They gave frail nursing home residents 6 grams of C8/C10 mixed MCTs per day — roughly one teaspoon — mixed into their evening meal. After 90 days, the research found: Full trial data in Article 5

How might this work? Researchers believe three pathways are involved. First, C10 activates PGC-1α through the sympathetic nervous system. PGC-1α is a protein that tells cells to make more and better mitochondria. Second, C10 raises acyl-ghrelin, which stimulates growth hormone — a key driver of muscle protein building. Third, the ketones produced from C10 provide an alternative fuel for muscles. When muscles use ketones for energy, they burn less protein — which means more protein goes toward building and maintaining muscle tissue. This is called the nitrogen-sparing effect.

6. TriCaprin and Heart Health Research

The heart health story for tricaprin starts in 1966. A Norwegian doctor named Paul Leren ran a five-year clinical trial — the Oslo Diet-Heart Study — with 412 men who had already had a heart attack. He changed their diets to include specific fats, including tricaprin. The results showed a 31% reduction in repeat heart attacks and measurable regression (shrinkage) of coronary plaque compared to the control group. Full Oslo study analysis →

In 2025, a research team from Osaka University published a study in Nature Cardiovascular Research. It looked at patients with a rare heart condition called TGCV — Triglyceride Deposit Cardiomyovasculopathy. In this condition, the heart cannot properly use long-chain fats for energy. Without fuel, the heart muscle fails. Researchers gave these patients tricaprin as a dietary supplement. The result: 100% three-year survival, compared to very poor outcomes with standard treatment.

Why does this matter for people without TGCV? Because the mechanism — tricaprin bypassing a broken fat metabolism pathway to deliver energy directly to heart muscle cells — is relevant to a wider group. Many people with type 2 diabetes, insulin resistance, or older adults may have reduced fat metabolism efficiency in the heart. Tricaprin's ability to bypass that blockade may have broader relevance, though this has not yet been proven in large clinical trials.

There is also the LCAT connection. LCAT is an enzyme that helps clear cholesterol from artery walls. C10 may activate LCAT, which would support a process called reverse cholesterol transport — where cholesterol is carried away from arteries back to the liver. This is the biological pathway that researchers believe may explain Leren's 1966 plaque regression results.

7. TriCaprin vs. MCT Oil

Many people have heard of MCT oil, which has become popular in the wellness community. MCT stands for medium-chain triglycerides. But not all MCT oils are the same — and the differences matter scientifically. Full comparison in Article 4

The key point: most commercial MCT oils are dominated by C8. The specific biological effects linked to tricaprin — PPARγ activation, LCAT stimulation, heart muscle energy delivery — are attributed to C10. A product labeled "MCT oil" is not the same as tricaprin unless it specifies high C10 content.

8. Who Is Researching TriCaprin?

Osaka University, Japan has been the world leader in TGCV research. Dr. Katsumi Hirano and his colleagues have maintained the world's most comprehensive registry of TGCV patients for over two decades. Their 2025 publication in Nature Cardiovascular Research documented the long-term cardiac recovery data. The Osaka Origin Story

Showa Women's University, Tokyo is where researchers Osamu Ezaki and Sakiko Abe ran the clinical trial series on C10 and muscle function in aging adults. Their combined 2023 analysis in Frontiers in Nutrition is the most cited human clinical dataset on C10 and sarcopenia.

University College London (UCL) contributed foundational mechanistic research. A 2014 study by Dr. Sophie Hughes and colleagues in the Journal of Neurochemistry was among the first to clearly show that C10 — and not C8 — is the MCT fraction that activates PPARγ and drives mitochondrial biogenesis.

Norway (historical): Dr. Paul Leren's Oslo Diet-Heart Study, published in the mid-1960s, remains the original human clinical dataset showing coronary plaque regression with a tricaprin-containing dietary protocol.

Research is still relatively limited compared to drugs like statins, which have been studied in hundreds of thousands of patients. But the geographic and disciplinary spread — cardiology, geriatrics, neurology, metabolism — suggests growing scientific interest across multiple fields.

9. Safety and Scientific Caution

Based on available research, C10 and tricaprin appear to be safe for most adults in the doses studied. The most common side effects from MCTs in general are digestive — nausea, loose stools, or stomach discomfort — especially when taken on an empty stomach or at high doses. Starting with a small amount and gradually increasing the dose typically reduces these effects.

Tricaprin is not a drug. It has not been evaluated by the FDA for the treatment or prevention of any disease. Nothing in the research reviewed here should be interpreted as medical advice. People with existing heart conditions, metabolic diseases, or those taking medications should always consult a physician before making dietary changes.

10. Key Takeaways